Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels

doi:10.3748/wjg.v17.i47.5166

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 47

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6454)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

609

HTML

5380

Figures (1-2)

236

Tables (1-1)

229

Sum=6454

Dec 21, 2011 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (49)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 21, 2011; 17(47): 5166-5171
Published online Dec 21, 2011. doi: 10.3748/wjg.v17.i47.5166

Full Size Figure Download Figure

Figure 2 Fecal calprotectin levels at baseline, and 2 and 6 wk after introduction of infliximab therapy showing the individual variation in children with inflammatory bowel disease.

Citation: Hämäläinen A, Sipponen T, Kolho KL. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol 2011; 17(47): 5166-5171
URL: https://www.wjgnet.com/1007-9327/full/v17/i47/5166.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i47.5166